Low-dose trimethoprim-sulfamethoxazole alone and in association with zidovudine for prevention and treatment of murine Pneumocystis carinii pneumonia.
Low-dose trimethoprim-sulfamethoxazole (TMP-SMX) alone was found to be as effective as low-dose TMP-SMX plus zidovudine and standard-dose TMP-SMX alone in preventing and treating Pneumocystis carinii pneumonia (PCP) in an immunosuppressed-rat model. Zidovudine alone had no preventive or curative effect on PCP. We conclude that the initially reported reduced incidence of PCP in human immunodeficiency virus-infected patients treated with zidovudine alone is not due to anti-P. carinii activity of zidovudine. Furthermore, the clinical efficacy of low-dose TMP-SMX for the prevention and treatment of PCP should be further investigated.
Brun-Pascaud
M
M
Institut National de la Santé et de la Recherche Médicale, U. 13, Hôpital Claude Bernard, Paris, France.
Girard
P M
PM
Pocidalo
J J
JJ
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D007165:Immunosuppression Therapy; D008297:Male; D051379:Mice; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy* / Q000517:prevention & control; D051381:Rats; D017208:Rats, Wistar; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000008:administration & dosage / Q000627:therapeutic use*; D015215:Zidovudine / Q000008:administration & dosage / Q000627:therapeutic use*
D015215:Zidovudine; D015662:Trimethoprim, Sulfamethoxazole Drug Combination